Irbesartan/Hydrochlorothiazide Activase Pharmaceuticals (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to lower blood pressure. It is used for the following recognized indications:

• Essential hypertension: reduces systolic and diastolic blood pressure in adults.
• Hypertension requiring combination therapy: provides additive pressure‑lowering when a single agent is insufficient.
• Hypertension with fluid retention: adds diuretic effect to control volume overload and improve blood‑pressure control.

• Irbesartan selectively blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. The dual actions produce additive reductions in systemic vascular resistance and circulating fluid, resulting in lower arterial pressure.

Common Side Effects

• Dizziness or light‑headedness.
• Headache.
• Fatigue or weakness.
• Increased urinary frequency.
• Mild electrolyte disturbances, such as low potassium.
• Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance.
• Acute kidney injury or worsening renal function.
• Hyperkalemia.
• Marked hypotension.
• Allergic reactions, including rash or angioedema.
• Rare cases of pancreatitis.

Before initiating therapy, clinicians should consider several safety measures:

• Renal function monitoring: assess serum creatinine and eGFR regularly.
• Electrolyte assessment: check potassium and sodium levels, especially with diuretic use.
• Hepatic impairment: use with caution in patients with severe liver disease.
• Diabetes mellitus: monitor blood glucose as thiazides may affect glycemic control.
• Concomitant NSAIDs: avoid or use cautiously due to increased risk of renal dysfunction.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several drug classes:

Major Interactions (Avoid)

• Aliskiren in diabetic patients: increased risk of renal impairment.
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• Dual renin‑angiotensin blockade (ACE inhibitor or another ARB): heightened hypotension and renal risk.
• NSAIDs: may reduce antihypertensive effect and impair renal function.
• Lithium: increased lithium levels and toxicity.

Moderate Interactions (Monitor Closely)

• Additional thiazide diuretics: monitor electrolytes and volume status.
• CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan concentrations.
• Antacids containing aluminum or magnesium: may reduce absorption of irbesartan.
• Digoxin: possible alteration of serum digoxin levels.
• Warfarin: monitor INR for potential changes in anticoagulation.